Quick answers
- What is Nifedipine used for?
- The FDA-approved label (Nifedipine, Preferred Pharmaceuticals Inc., August 4, 2026) says: “I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Nifedipine have a boxed warning?
- No. None of the 86 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Nifedipine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Nifedipine been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started July 2, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Nifedipine?
- 32 companies list prescription products of Nifedipine in the FDA NDC Directory, including Bryant Ranch Prepack, Northwind Health Company, LLC and A-S Medication Solutions.
What Nifedipine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
I.Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. …
— FDA label: Nifedipine, Preferred Pharmaceuticals Inc., effective August 4, 2026. Read the full label on DailyMed →
The FDA has 86 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 86 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, extended release · Tablet, film coated, extended release · Capsule |
|---|---|
| Route | Oral |
| Prescription products | 130 in the FDA NDC Directory |
| Brand names | Procardia XL |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| nifedipine 10 mg capsule | Generic | $0.2724 per capsule |
| nifedipine 20 mg capsule | Generic | $0.6770 per capsule |
| nifedipine 30 mg tablet, extended release | Generic | $0.1095–$0.1305 per tablet 4 packages, lowest to highest |
| nifedipine 30 mg tablet, film coated, extended release | Generic | $0.1305 per tablet |
| nifedipine 60 mg tablet, extended release | Generic | $0.1561–$0.1678 per tablet 6 packages, lowest to highest |
| nifedipine 60 mg tablet, film coated, extended release | Generic | $0.1678 per tablet |
| nifedipine 90 mg tablet, extended release | Generic | $0.2635–$0.2660 per tablet 5 packages, lowest to highest |
| nifedipine 90 mg tablet, film coated, extended release | Generic | $0.2660 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack13 products
- Northwind Health Company, LLC7 products
- A-S Medication Solutions7 products
- PD-Rx Pharmaceuticals, Inc.6 products
- Upsher-Smith Laboratories, LLC6 products
- Aphena Pharma Solutions - Tennessee, LLC6 products
- Ingenus Pharmaceuticals, LLC6 products
- Zydus Pharmaceuticals USA Inc.6 products
- Zydus Lifesciences Limited6 products
- Golden State Medical Supply, Inc.6 products
- Chartwell RX, LLC5 products
- Oceanside Pharmaceuticals5 products
- Proficient Rx LP5 products
- Major Pharmaceuticals4 products
- Cardinal Health 107, LLC4 products
- NuCare Pharmaceuticals, Inc.4 products
- AvPAK3 products
- Aurobindo Pharma Limited3 products
- Alembic Pharmaceuticals Inc.3 products
- American Health Packaging3 products
- Alembic Pharmaceuticals Limited3 products
- Lannett Company, Inc.3 products
- Remedyrepack Inc.3 products
- Ascend Laboratories, LLC3 products
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.2 products
- Pfizer Laboratories Div Pfizer Inc2 products
- Redpharm Drug2 products
- Preferred Pharmaceuticals Inc.2 products
- St. Mary's Medical Park Pharmacy2 products
- NCS HealthCare of KY, LLC dba Vangard Labs1 product
- Elite Pharmaceutical Solution, Inc.1 product
- Coupler LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA019684 PROCARDIA XL | Pfizer | September 6, 1989 | 22, latest November 9, 2021 2021: Labeling · 2015: Labeling · 2014: Manufacturing (CMC) |
Generic approvals (16)
- ANDA072781Acella · July 30, 1993
- ANDA075289Valeant Pharms North · September 27, 2000
- ANDA075269Valeant Pharms North · December 4, 2000
- ANDA076070Valeant Pharms North · August 16, 2002
- ANDA077127Osmotica Pharm Us · November 21, 2005
- ANDA202644Heritage Pharma · April 25, 2013
- ANDA203126Twi Pharms · April 3, 2014
- ANDA202987Novast Labs · August 25, 2016
- ANDA210012Zydus Pharms · December 19, 2017
- ANDA210184Zydus Pharms · June 29, 2018
- ANDA210614Novast Labs · March 12, 2019
- ANDA212016Elite Pharm Solution · November 18, 2020
- ANDA213361Aurobindo Pharma · July 19, 2021
- ANDA216067Alkem Labs Ltd · March 29, 2022
- ANDA216896Alembic · November 18, 2022
- ANDA077410—
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 2, 2021 · Class II · Terminated · D-0652-2021
Failed Dissolution Specification: Out of specification for dissolution during routine stability testing.
NIFEdipine EXTENDED-RELEASE TABLETS, USP 30 mg Rx only packaged as a) 100 count unit dose carton, NDC 0904-7080-61; b) 50 count unit dose carton, NDC 0904-7080-06: Distributed by: Ingenus Pharmaceuticals, LLC Orlando, FL — The Harvard Drug Group
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Nifedipine, Preferred Pharmaceuticals Inc., effective August 4, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →